Michael Ryskin
Stock Analyst at B of A Securities
(1.76)
# 3,039
Out of 4,784 analysts
34
Total ratings
47.83%
Success rate
-3.3%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.36 | +238.98% | 3 | Mar 3, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $54 → $60 | $47.83 | +25.44% | 4 | Mar 3, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $475 → $535 | $415.87 | +28.65% | 2 | Feb 4, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $159.21 | +29.39% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $43.14 | -7.28% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $5.92 | +60.47% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $9.91 | +142.18% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $16.18 | +48.33% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $163.11 | +10.35% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $5.81 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $19.96 | +160.52% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.70 | +270.37% | 2 | Nov 10, 2021 |
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.36
Upside: +238.98%
Tempus AI
Mar 3, 2025
Maintains: Neutral
Price Target: $54 → $60
Current: $47.83
Upside: +25.44%
IDEXX Laboratories
Feb 4, 2025
Maintains: Neutral
Price Target: $475 → $535
Current: $415.87
Upside: +28.65%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $159.21
Upside: +29.39%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $43.14
Upside: -7.28%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $5.92
Upside: +60.47%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $9.91
Upside: +142.18%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $16.18
Upside: +48.33%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $163.11
Upside: +10.35%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.81
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $19.96
Upside: +160.52%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.70
Upside: +270.37%